Navigation Links
RZN Nutraceuticals Receives United States Patent & Trademark Office Notice of Allowance for Proprietary HerbaZorb(TM) Absorption and Delivery System Technology Used in Popular Arthri-Zen Relief(R) and Migra-Zen Relief PLUS(R) Products
Date:9/11/2009

MIAMI, Sept. 11 /PRNewswire/ -- RZN Nutraceuticals, Inc.,(www.rznnutra.com) a leading developer of proven effective herbal products which have been clinically tested on sufferers of severe arthritis and migraines has announced receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for the firm's absorption and delivery system process methodology patent application, a technology RZN has named HerbaZorb(TM). Two of the firm's most popular product offerings, Arthri-Zen Relief(R) and Migra-Zen Relief(R) PLUS capsules already use the technology in their manufacture. The use of this preparation method ensures the rapid and effective absorption of active ingredients.

"We're very pleased that the U.S. Patent and Trademark Office has recognized HerbaZorb as a patentable delivery system that allows herbal supplements and functional foods to be absorbed with full potency intact," said Mark Lubin, founder of RZN Nutraceuticals, Inc., and a 25-year veteran biomedical engineer and research scientist in the fields of orthopedics, joint diseases, implantable cardiac devices, materials science and medical chemistry.

Among the proprietary characteristics of HerbaZorb noted in the patent application are that it protects beneficial phytochemicals of herbs and herbal extracts from being digested prior to entering the bloodstream, providing a significant advantage to both producers of herbal products and those who consume them. "The basis for our patent is that our delivery system represents a breakthrough in the field of bioavailability, the process by which active ingredients are delivered to the bloodstream intact, ensuring their maximum usefulness in the body." Mr. Lubin commented.

According to company President Robert Hunt, "It is very satisfying to gain this important recognition for HerbaZorb, especially as we continue making the process available to other manufacturers who want us to prepare their herbal ingredients using this new technology."

Clinical researchers have long studied the role absorption plays in the bioavailability of active ingredients ingested into the body. According to the Physician's Desk Reference, only 10 to 20 percent of vitamins and minerals taken orally in tablet form are actually absorbed into the bloodstream.

"My goal has always been to develop the most effective and natural pain relief formulations possible, which resulted in the Arthri-Zen Relief(R) and Migra-Zen Relief(R) PLUS family of products," Mr. Lubin stated. "With the advances in absorption offered by HerbaZorb, we can ensure that everyone in the industry using herbal blends can benefit from maximum bioavailability so the active ingredients in them are utilized most fully by the human body."

RZN Nutraceuticals' products are marketed direct to natural accounts, through private label, catalogue sales, practitioner offices, health clubs and on company's website, www.rznnutra.com. Future distribution plans include national drug store chains and natural supplement outlets.

For more information on Migra-Zen Relief Plus(R) or the three Arthri-Zen Relief(R) formulations, visit www.rznnutra.com, or contact RZN President Robert Hunt 904-213-8232.

For media inquiries, contact Jennifer Bryan of Christie Communications (www.christiecomm.com) at 805-969-3744.


'/>"/>
SOURCE RZN Nutraceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. HBA X-Ceuticals Conference Explores The Emerging Market of Cosmeceuticals and Nutraceuticals
2. Nutrition 21 Launches New Innovative PRESCRIPTIX(TM) Nutraceuticals Product Line
3. Valensa International and Parry Nutraceuticals Join Forces in the Global Natural Products Marketplace
4. Valensa and Parry Nutraceuticals Introduce Organic SpiruZan(TM) Spirulina/Astaxanthin Complex as Lifestyle Support for a Fast-Paced World
5. Nutraceuticals could prevent diabetes
6. Berkeley Premium Nutraceuticals Pushes Forward
7. UM receives grant to support graduate students in the family nurse practitioner program
8. Par Pharmaceutical Receives Final Approval To Market Generic Starlix(R)
9. CBM-US Receives $3 Million Grant To Fund HIV/AIDS Prevention and Care Efforts in Africa
10. Solos Endoscopy, Inc. Receives Purchase Order from One of the Major Healthcare Systems in Missouri
11. Ascenta Therapeutics Receives Clearance to Initiate Clinical Trials With AT-406
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... PAPA Healthcare, Inc. announced today, ... “PAPA Healthcare helps fill gaps, provide essential insights, and improve productivity.” The ... by leveraging PAPA Healthcare’s post-acute productivity and analytics solutions. , St. Vincent’s Home ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... to funding innovative lymphoma research and serving the lymphoma community through a comprehensive ... Texas as a part of its national Swirl: A Wine Tasting Event series ...
(Date:9/19/2017)... ... September 19, 2017 , ... The American ... Americans to watch for the discomforts and hidden dangers of foot fungus, particularly ... everyone is at risk for developing fungal infections on the feet or toenails, ...
(Date:9/19/2017)... ... September 19, 2017 , ... The Workgroup for Electronic Data Interchange (WEDI) ... efficiencies in healthcare information exchange and a trusted advisor to the U.S. Department of ... paper, entitled Barriers to Adoption of the ERA and EFT Transactions . ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... Driving Dynamics ... Safety Training Company by Training Industry Inc. as part of its mission to continually ... , Selection to the first annual 2017 Top 20 Health and Safety Training Companies ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... 2017  Eli Lilly and Company (NYSE: ... operations to more efficiently focus resources on developing ... Global workforce reductions, including those from a U.S. ... approximately 3,500 positions. With the ... of approximately $500 million that will begin to ...
(Date:9/7/2017)... Ind. , Sept. 7, 2017  Zimmer Biomet ... in musculoskeletal healthcare, today announced that it will be ... Global Healthcare Conference at the Grand Hyatt hotel in ... 11, 2017 at 11:40 a.m. Eastern Time. ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
(Date:9/6/2017)... PDI , a leader in infection prevention products and ... focused on the role of chlorhexidine gluconate (CHG) in ... Annual Scientific Meeting of the Association for Vascular Access. ... Phoenix Convention Center in ... feature PDI,s Prevantics® Device Swab as the ...
Breaking Medicine Technology: